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Abstract
Matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) regulate epithelial-mesenchymal transition
(EMT) critical for the development of epithelial organs as well as cancer cell invasion. TIMP-1 is frequently overexpressed in
several types of human cancers and serves as a prognostic marker. The present study investigates the roles of TIMP-1 on the
EMT process and formation of the lumen-like structure in a 3D Matrigel culture of MDCK cells. We show that TIMP-1
overexpression effectively prevents cell polarization and acinar-like structure formation. TIMP-1 induces expression of the
developmental EMT transcription factors such as SLUG, TWIST, ZEB1 and ZEB2, leading to downregulation of epithelial
marker and upregulation of mesenchymal markers. Importantly, TIMP-19s ability to induce the EMT-like process is
independent of its MMP-inhibitory domain. To our surprise, TIMP-1 induces migratory and invasive properties in MDCK cells.
Here, we present a novel finding that TIMP-1 signaling upregulates MT1-MMP and MMP-2 expression, and potentiates MT1-
MMP activation of pro-MMP-2, contributing to tumor cell invasion. In spite of the fact that TIMP-1, as opposed to TIMP-2,
does not interact with and inhibit MT1-MMP, TIMP-1 may act as a key regulator of MT1-MMP/MMP-2 axis. Collectively, our
findings suggest a model in which TIMP-1 functions as a signaling molecule and also as an endogenous inhibitor of MMPs.
This concept represents a paradigm shift in the current view of TIMP-1/MT1-MMP interactions and functions during cancer
development/progression.
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Introduction
The epithelial-mesenchymal transition (EMT) is a morphoge-
netic process essential for all Metazoan embryogenesis. A partial
EMT occurs during branching morphogenesis or tubulogenesis for
the development of epithelial organs such as kidney, mammary
gland, lung and salivary gland [1,2,3]. A phenotypic hallmark of
EMT is that stationary epithelial cells, undergoing this biological
process, acquire mesenchymal-like migratory properties. Impor-
tantly, studies suggest that carcinoma cells can re-activate the
developmental EMT-like process during tumor cell invasion and
metastasis [4]. Interestingly, genes involved in EMT are often
conserved in different organs, throughout evolution, and as well
during tumor progression. The three-dimensional (3D) Madin-
Darby canine kidney (MDCK) cell culture is one of the most
widely used experimental models to study the molecular mecha-
nisms by which the EMT, lumen formation, and branching
morphogenesis are regulated [5,6,7]. Accordingly, the MDCK
model has been utilized to investigate the pathogenic EMT
program that disrupts tightly regulated normal epithelial biology,
contributing to human diseases such as organ fibrosis and
carcinoma [8,9,10,11].
Evidence suggests that matrix metalloproteinases (MMPs) and
their endogenous inhibitors, tissue inhibitors of metalloproteinase
(TIMPs), play critical roles during both developmental and
pathological EMT. Increased expression of certain MMPs may
function to disrupt cell-cell contact through E-cadherin [12]. As
tumor progresses, tubular/ductal epithelial cells lose their epithe-
lial properties and acquire mesenchymal-like features including
loss of apical-basal cell polarity, acinar-like structures and cell-cell
tight junction proteins as well as loss of the ability to invade
through basement membranes and interstitial matrix. In an
MDCK model, mitogen-activated protein kinase (MAPK)-
regulated MMP-13 and TIMP-1 expression were involved in
controlling partial-EMT and re-differentiation [11]. Also, overex-
pression of membrane-type 1-matrix metalloproteinase (MT1-
MMP) resulted in differentiated and locally invading tumors [10].
Thus, deregulation of MMPs and/or TIMPs may result in the
pathologic EMT process.
Among MMPs and TIMPs, TIMP-1 is frequently overexpressed
and shown to serve as a prognostic marker in several types of
human cancers including breast cancer, prostate cancer, lung
cancer, melanoma, multiple myeloma, and glioblastoma
[13,14,15,16,17,18,19,20,21]. This seemed at first counter-intui-
tive considering its prominent role in MMP inhibition, thereby
suppressing matrix degradation necessary for tumor cell invasion.
Importantly, we and others have demonstrated that TIMP-1 can
function as a signaling molecule independent of its MMP-
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survival program [22,23,24,25,26,27,28]. In breast epithelial cells,
TIMP-1 interacts with the tetraspanin CD63 and subsequently
activates an integrin b1 signaling complex, leading to activation of
focal adhesion kinase (FAK), phosphoinositide 3-kinases (PI3K),
Akt, and ERKs [22,23,24,25]. In the MCF10A morphogenesis
assay within a 3D Matrigel matrix, TIMP-1 signaling disrupts cell
polarization and inhibits apoptosis in centrally located cells,
thereby preventing the formation and maintenance of the hollow
acinar-like structure [25].
The present study focused on the effects of TIMP-1 expression
on lumen formation, EMT marker expression, and migratory/
invasive properties of non-malignant immortalized Madin-Darby
canine kidney (MDCK) cells. We report herein that while control
MDCK cells cultured within a Matrigel matrix formed polarized
acinar-like structures with hollow lumens, MDCK cells overex-
pressing TIMP-1 exhibited disrupted cell polarization and reduced
cell death in the centers of the spheroids, and consequently, these
cells were unable to undergo the acinar morphogenetic program.
In addition, TIMP-1 induces expression of EMT transcription
factors including SLUG, TWIST, ZEB1 and ZEB2, leading to
downregulation of epithelial cadherin (E-cadherin) and upregula-
tion of mesenchymal markers such as N-cadherin, fibronectin,
and vimentin. Interestingly, contrary to the reported anti-
migratory and anti-invasive properties of TIMP-1 [29,30,31],
our data identify TIMP-1 as a promoter of MDCK cell migration
and invasion. Lastly, we present a novel finding that TIMP-1
signaling induces MT1-MMP expression at both RNA and protein
levels. Importantly, TIMP-1-induced EMT-like phenotypic chang-
es and increased MT1-MMP expression are independent of
TIMP-19s MMP-inhibitory domain. Taken together, the present
study provides a new molecular insight into the novel oncogenic
activity of TIMP-1 during cancer progression.
Materials and Methods
Reagents and Antibodies
Mitomycin C, concanavalin A (ConA) were obtained from
Sigma (St. Louis, MO). GM6001 was obtained from Calbiochem
(San Diego, CA). Growth factor-reduced basement membrane
Matrigel (GFR Matrigel) was purchased from BD Biosciences
Discovery Labwares (Palo Alto, CA). Anti-TIMP-1 monoclonal
antibody (Clone 102D1) was purchased from NeoMarkers, Inc.
(Fremont, CA). Monoclonal antibodies against the N-terminus of
MMP-2 and the catalytic domain of MT1-MMP were purchased
from Millipore (Billerica, MA). Anti-E-cadherin mAb was
purchased from BD transduction laboratories (San Jose, CA).
Anti- b-actin mAb, anti-vimentin mAb, and peroxidase conjugat-
ed antibodies against mouse or rabbit IgG were purchased from
Sigma (St. Louis, MO). Anti-GAPDH mAb was purchased from
Santa-Cruz Biotechnology (Santa Cruz, CA). The FAK100 actin
cytoskeleton kit was purchased from Chemicon International, Inc.
(Temecula, CA).
Cell Culture
Canine kidney epithelial MDCK cells were purchased from the
American Type Tissue Collection (ATCC) and cultured at 37uCi n
a humidified incubator with 5% CO2, and DMEM media were
supplemented with 10% fetal bovine serum, 2 mM glutamine,
100 units/ml penicillin, and 100 mg/ml streptomycin (Life
Technologies Inc., Carlsbad, CA).
Establishment of Human TIMP-1 and its Mutants
Overexpressing MDCK Cells
Full-length TIMP-1 (amino acids 1–184) (T1) or the partial N-
terminal and C-terminal domain (amino acids 66–184) of TIMP-1
(T1D) were amplified by PCR using a vector carrying hTIMP-1
cDNA from Open Biosystems (Huntsville, AL), and the various
restriction enzyme sites were introduced respectively according to
the target vector. The signal peptide was included in the constructs
to maintain secretion. The pcDNA3.1 control, pcDNA3.1-T1 and
pcDNA3.1-T1D vectors were transfected into MDCK cells using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. Subsequently, cells were subjected to
400 mg/ml G418 antibiotic selection for 14 days and pooled for
further analysis. Pooled populations expressing wild type TIMP-1
proteins are referred to as MDCK-T1 cells and pooled popula-
tions expressing N-terminal MMP inhibitory domain-deleted
TIMP-1 (T1D) proteins are referred to as MDCK-T1D. Control
cells transfected with pcDNA3.1 plasmid without an insert are
referred to as MDCK-Neo cells. In order to detect T1D protein
expression, the final PCR products for TIMP-1 and T1D were
also cloned into p3XFLAG-CM-14 expression vectors. These
expression vectors were also transfected into MDCK cells.
Cell Proliferation Assay
Cell proliferation was assessed by MTT assay as well as trypan
blue dye exclusion assay. 2000 cells were plated in a 96-well plate
and cell viability was determined at the indicated time points by
MTT assay as instructed by the manufacturer. Briefly, after
incubation with MTT (0.5 mg/ml) for 4 h at 37uC, formazan
precipitates formed by mitochondrial dehydrogenases in viable
cells were extracted with acidic isopropanol. The absorbance of
the converted dye was measured at a wavelength of 570 nm and
the results were expressed as a percentage (%) compared to the
number at time 0. For trypan blue dye exclusion assay, cells were
seeded at 1610
4cells/60 mm plate. At the indicated time points,
cells were stained with 0.4% Trypan blue dye solution (Sigma
Chemical Co., St Louis, MO, USA) for 10 min and live cells,
capable of excluding the dye with intact membranes, were counted
using a hemocytometer. At least three independent experiments
were performed for statistical analysis.
MT1-MMP Knockdown
MDCK-T1 and MDCK-T1D cells were transfected with small
interfering RNA (siRNA) targeting MT1-MMP or non-specific
control siRNA using Lipofectamine 2000 according to manufac-
turer’s protocol. Two siRNA target sequences for canine MT1-
MMP were synthesized by Dharmacon, Inc., Lafayette, CO, USA
(set1, 59- GGG AAC AAA UAC UGG AAA UUU -39,5 9- AUU
UCC AGU AUU UGU UCC CUU-39 and set 2; 59- GGG CUG
AGA UCA AGG CCA AUU-39,5 9- UUG GCC UUG AUC
UCA GCC CUU-39). After transfection, cells were maintained in
DMEM medium with 5% FBS for 72 hours before pro-MMP-2
activation assay.
Immunoblot Analysis
Cells were lysed with ice-cold RIPA buffer (0.05 M Tris–HCl,
pH 7.4, 0.15 M NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM
EDTA) supplemented with 1 mM phenylmethylsulfonyl fluoride
(PMSF), 2 mM sodium metavanadate (NaVO3), 1 mM sodium
fluoride (NaF), and protease inhibitor cocktail. The protein
concentration in the lysates was determined by the BCA
procedure (Thermo Scientific). Equal amounts of protein samples
in SDS sample buffer [1% SDS, 62.5 mM Tris-HCl (pH 6.8),
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38773Figure 1. TIMP-1 induces cell survival signaling in MDCK cells, independent of its MMP-inhibitory domain. A. Schematic representation
of the T1 and T1D proteins. The 12 cysteine (C) residues are linked to form six disulfide bonds; the 23 amino acids-long secretion signal sequence
(amino acid 1–23) is indicated. A TIMP-1 mutant encoding the C-terminal and partial N-terminal (amino acid 66–184) regions of human T1 is indicated
as TID. B. (Left Panel) RT-PCR analysis of TIMP-1 mRNA in MDCK-Neo, MDCK-T1 and MDCK-T1D cells using primers common to human and canine
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blue] were boiled for 5 min and subjected to reducing SDS-
PAGE. After electrophoresis, the proteins were transferred to a
nitrocellulose membrane. The membrane was blocked with 5%
nonfat dry milk in 100 mM Tris-HCl (pH 7.5), 150 mM NaCl,
and 0.2% Tween 20 (T-TBS) for 1 hr at room temperature. The
membranes were incubated with T-TBS containing 5% milk and
the primary antibodies. After three washes with T-TBS, the blot
was incubated with the appropriate horseradish peroxidase-
conjugated secondary antibodies. The antigen was detected using
the Western Blot Chemiluminescence Reagent Plus (Perkin Elmer
Life Sciences, Inc., Boston, MA), according to the manufacturer’s
instruction.
Semi-quantitative RT-PCR
mRNA was purified from cells using the RNeasy kit (Qiagen,
Valencia, CA, USA). cDNA synthesis was performed with
Superscript III First-Strand Synthesis System (Invitrogen, Carls-
bad, CA, USA), followed by PCR using GoTaq Flexi DNA
Polymerase (Promega, Madison, WI, USA). Forward and reverse
canine specific forward and reverse primers used are as follows: E-
Cadherin: 59- AAAACCCACAGCCTCATGTC-39,5 9- CACC-
TGGTCCTTGTTCTGGT-39; N-cadherin: 59-CCCAAGACA-
AGCGACTAAGC-39,5 9-TGACAGCTGACCTGAGATGG-39;
Fibronectin: 59-GGTTTCCCATTATGCCATTG-39,5 9-TTCC-
AAGACATGTGCAGCTC-39; Vimentin: 59-CCGACAGGAT-
GTTGACAATG-39,5 9-TCAGAGAGGTCGGCAAACTT-39;
MMP2: GGATGCTGCCTTTAATTGGA, 59-CGCACCCTT-
GAAGAAGTAGC-39; MMP9: 59-CAAACTCTACGGCTTC-
TGCC-39,5 9-TGGCACCGATGAATGATCTA-39; MT1-MMP:
59- GGAGACAAGCACTGGGTGTT-39,5 9- CATCACTGCC-
CATGAATGAC-39; SLUG: 59-AAGCAGTTGCACTGTGAT-
GC-39,5 9-GCAGTGAGGGCAAGAAAAAG-39; SNAIL: 59-
CAAGGCCTTCAACTGCAAAT-39,5 9-AAGGTTCGGGAA-
CAGGTCTT-39; TWIST: 59-ACGAGCTGGACTCCAAGA-
TG-39,5 9- CACGCCCTGTTTCTTTGAAT-39; ZEB-1: 59-
AGGCAGATGAAGCGAGATGT-39,5 9-TCTGGTCCTCTT-
CAGGTGCT-39; ZEB-2: 59-ACGACATTCTGCAAGCCTCT-
39,5 9-GTGTCACTGCGCTGAAGGTA-39; GAPDH: 59-AA-
CATCATCCCTGCTTCCAC-39,5 9-GACCACCTGGTCCT-
CAGTGT-39; TIMP-1 (common to human and canine TIMP-
1): 59- CACCAGAGAACCCACCATGGC-39,5 9- CACTCTG-
CAGTTTGCAGG-39.
Gelatin Zymography
Gelatin zymography of conditioned media was performed using
10% Tris-glycine SDS-polyacrylamide gels containing 0.1%
gelatin. Briefly, serum-free conditioned media were mixed with
Laemmli sample buffer without reducing agents or heating and
then subjected to 10% SDS-PAGE. The gels were then incubated
(30 min at room temperature) in renaturating buffer (2.5% Triton
X-l00 in H2O), rinsed in distilled H20, and equilibrated for an
additional 30 min in developing buffer (50 mM Tris buffer,
pH 8.0, 200 mM NaC1, 5 mM CaCl2, and 0.02% Brij-35)
followed by an incubation (16 h at 37uC) in fresh developing
buffer. The gels were then stained with 0.5% Coomassie Blue
R250 in a solution of 10% methanol and 5% acetic acid followed
by destaining in 10% methanol and 5% acetic acid.
Caspase Activity Assay
Cells were lysed in cell extract buffer [150 mmol/L NaCl,
50 mmol/L Tris-HCL (pH 7.5), 0.5 mmol/L EDTA, and 0.5%
NP40], kept on ice for 30 minutes, and centrifuged at 15,000 Xg
for 10 minutes. Fifty microliters of the cytosolic fraction were
incubated for 60 minutes at 37uC in a total volume of 200 uL of
caspase buffer [20 mmol/L HEPES (pH 7.5), 50 mmol/L NaCl,
and 2.5 mmol/L DTT] containing 25 mol/L Ac-DEVD-AMC
for caspase-3-like activity (BioSource International, Inc., Camar-
illo, CA). 7-Amino-4-methylcoumarin fluorescence, released by
caspase activity was measured at 460 nm using 360 nm excitation
wavelength on a Spectra Maxi Germini fluorescence plate reader
(Molecular Devices, Menlo Park, CA). Caspase activity was
normalized per microgram of protein as determined with a
bicinchoninic acid protein assay reagent (Pierce).
Fluorescence-Activated Cell Sorting (FACS) Analysis
Apoptotic cell number was determined by FACS analysis using
violet ratiometric membrane asymmetry Probe, 4’-N,N-diethyla-
mino-6-(N,N, N-dodecyl-methylamino-sulfopropyl)-methyl-3-hy-
droxyflavone (F2N12S) as recommended by the manufacturer’s
protocol. Briefly, suspended cells were incubated for 5 min with
200 nM F2N12S solution and 1 uM SYTOX AADvanced
TM
dead cell stain solution. Apoptotic cells were analyzed by Becton
Dickinson FACSscan flow cytometer and BD FACSDiva software.
Cell Migration and Invasion Assay
For a scratch wound assay for cell migration, cells were grown
to 90% confluence in complete medium in a 6-well plate and pre-
treated with mitomycin C (25 ug/ml) for 30 min before an injury
line was made using a 2-mm-wide plastic pipette tip. After rinsing
with PBS, cells were allowed to migrate in serum-free media for
16 hr, and photographs were taken (X40) to assess cell motility.
Cell migration was also assessed using 24-well Transwell chambers
with polycarbonate filters (8 um pore size) (Corning Costar,
Cambridge, MA). The cells were resuspended in 0.1% BSA
containing DMEM medium and the lower compartments of the
wells were filled with 750 ul of 1% FBS containing medium.
1610
5 cells were placed in the upper part of the Transwell and
incubated for 16 hr. The in vitro invasive property of cells was
assessed using a modified Boyden chamber assay. A total of 1610
5
cells were placed in the upper compartment of the invasion
chamber (BD BioCoat Matrigel Invasion Chamber, BD Biosci-
ences, Bedford, MA). For MMP inhibition experiments, 25 uM
GM6001 was added to the cells in the upper compartment of the
insert. The chambers were incubated for 16 hr at 37uC. The filters
were then stained with crystal violet. Quantification of the
migration or invasion assay was performed by counting the
number of cells at the lower surface of the filters.
TIMP-1 mRNA. B. (Right Panel) Immunoblot analysis of TIMP-1 in cell lysates or conditioned media (CM) using anti-TIMP-1 Ab that recognizes the N-
terminal domain of TIMP-1 (top panel) or anti-FLAG antibody (middle panel). C. Immunoblot analysis of Erk and Akt using MDCK-Neo, -T1, and –T1D
cell lysates. D-E. DEVDase activity in MDCK-Neo, MDCK-T1, and MDCK-T1D cells upon treatment with 0.5 uM staurosporine for 4 hr (D) and serum-
free culturing for 48 hr (E). DEVDase activity was normalized per microgram protein and each bar represents the mean 6 s.d. of triplicates in three
independent experiments. F-G. Apoptotic cells were quantified by FACS after F2N12S labeling and SYTOX AADvanced
TM dead cell stain. (F)
Representative FACS data without or with 0.5 mM staurosporine for 16 hr. (Upper left-dead cells; Lower left-apoptotic cells; Lower right-live cells). (G)
Bar graph represents the mean percentages of apoptotic cells 6 s.d. in the three independent experiment. Asterisk (*) indicates a P value ,0.001
using a Paired T-test.
doi:10.1371/journal.pone.0038773.g001
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Culture
Three-dimensional culture was carried out as previously
described (Debnath et al., 2002; Mills et al., 2004). Assay medium
(DMEM supplemented with 5% FBS, 50 U/ml penicillin, and
50 mg/ml streptomycin) containing 2% growth factor reduced
Matrigel (GFR Matrigel) (BD Biosciences, Bedford, MA) was
replaced every four days. At indicated time points, cells were
Figure 2. TIMP-1 signaling disrupts MDCK cell polarization and acini formation in a 3D Matrigel culture. Phalloidin staining (red) and
blue-fluorescent nuclear staining with DAPI in MDCK-Neo (A), -T1 (B), and –T1D (C) cells in a 3D Matrigel culture for indicated periods. D. Percentage
of polarized acini examined in cross sections through the middle of developing acini of MDCK-Neo at 12 days, and T1, T1D at 23 days. (More than 40
spheroids were analyzed for each condition from three independent experiments and the means + s.d. were shown). E-F. At the indicated time
points, MDCK-Neo, T1, T1D cell proliferation was assessed by trypan blue exclusion assay (E) or MTT assay (F). (Shown are means + s.d of three
independent experiments).
doi:10.1371/journal.pone.0038773.g002
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2+ and Mg
2+,
fixed in 4% paraformaldehyde at room temperature for 20 min,
and washed three times with PBS:Glycine buffer (130 mM NaCl,
7m M N a 2HPO4, 3.5 mM NaH2PO4, 100 mM glycine) for
10 min. Cells were permeabilized in 0.5% Triton X-100 in PBS
for 10 min at 4uC. After three washes with PBS, cells were
incubated with Rhodamine-conjugated phalloidin at room tem-
perature for 30 min. After three washes with PBS, the coverslips
were counterstained with DAPI (Roche applied Science, India-
napolis, IN) and mounted with anti-fade solution. Confocal
Figure 3. TIMP-1 regulates EMT markers and induces motility of MDCK cells, independent of its MMP-inhibitory domain. A. RT-PCR
analysis (left panel) of epithelial marker E-cadherin and mesenchymal markers N-cadherin, Fibronectin, and Vimentin. Immunoblot analysis (right
panel) of E-cadherin (after long and short exposures) and vimentin in MDCK-Neo, -T1, and –T1D cells. B. RT-PCR analysis of EMT transcriptional factors
SNAIL, SLUG, TWIST, ZEB1 and ZEB2. C. A scratch migration assay was performed in MDCK-Neo, -T1 and T1D cells for 18 h.
doi:10.1371/journal.pone.0038773.g003
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the Zeiss LSM510 confocal microscopy system equipped with
krypton-argon (488 and 568 lines) and ultraviolet (364 line) lasers.
Results
MDCK cells are non-malignant kidney epithelial cells that are
known to activate an acinar-like morphogenetic program when
cultured in 3-D conditions [32]. Moreover, MDCK cells can be
reprogrammed to undergo an EMT under various stimuli
[33,34,35]. Therefore, to examine the roles of TIMP-1 in
regulation of EMT-like process and morphogenesis, we established
MDCK cells engineered to overexpress wild-type TIMP-1
(referred to as MDCK-T1). To distinguish whether the TIMP-1
effects on EMT were mediated or not through inhibition of MMP
activity, we also generated MDCK cells overexpressing TIMP-1
mutant in which the N-terminal MMP-inhibitory domain was
deleted (referred to as MDCK-T1D), as also described elsewhere
(Liu et al., manuscript under review) (Fig. 1A-B). As expected,
purified recombinant T1D protein, lacking the binding site for
active MMPs, completely lost its ability to inhibit MMP-2 and
MMP-9 enzymatic activity (data not shown). As shown in Figure 1,
ERKs and Akt, two signaling molecules that we previously
identified as key mediators of the TIMP-1 survival pathway, were
constitutively activated in both MDCK-T1 and MDCK-T1D
cells. Consequently, both MDCK-T1 and MDCK-T1D cells were
resistant to apoptosis induction when compared to control
MDCK-Neo cells, as assessed by the caspase-like activity assay
(Fig. 1D-E) and FACS analysis using a violet ratiometric
membrane probe (Fig. 1F-G) upon staurosporine treatment or
growth factor withdrawal. These results demonstrate that TIMP-1
activation of cell survival signaling in MDCK cells is independent
of its MMP-inhibitory domain, consistent with previously findings
[22,23,24,25].
In a 3D Matrigel morphogenesis assay, it was previously shown
that the outer layer of polarized MDCK cells in contact with the
basement membrane survive, whereas the centrally located cells
undergo cell death, a process that leads to the formation of a
hollow acinar-like structure [32]. In agreement, MDCK cell
polarization became evident within the cell cluster after 8 days in a
3D-Matrigel matrix, and the cells formed a hollow acinar-like
structure within 12 days (Fig. 2A). In contrast, TIMP-1
overexpression prevented both polarization and cell death in
centrally located cells, consequently inhibiting the formation of the
hollow acinar structure (Fig. 2B). Interestingly, T1D expression
prevented the formation of the acinar structure as effectively as the
wild-type TIMP-1 (Fig. 2C). These results indicate that the ability
of TIMP-1 to interfere with cell polarization and promote cell
survival in the absence of cell contacts with basement membrane
are independent of its MMP-inhibitory domain. As previously
reported [36], TIMP-1 overexpression reduced the rate of cell
proliferation as determined by MTT and trypan blue dye
exclusion assays (Fig. 2E-F). It should be noted that TIMP-1
modulation of MDCK cell growth was independent of its MMP-
inhibitory domain since the comparable effects were seen between
wild-type TIMP-1 and T1D overexpression. To exclude the
possibility that the lack of MDCK-T1 and MDCK-T1D cell
polarization up to day 12 merely reflects delayed morphogenesis
due to reduced cell proliferation rates, the morphogenesis assay
was continued for 23 days (Fig. 2B and 2C). Under these
conditions, ,80% of MDCK-Neo cells displayed a well-polarized,
hollow acinar-structure, whereas only ,20% of MDCK-T1 and
MDCK-T1D cells formed polarized spheroids (Fig. 2D), demon-
strating a role for TIMP-1 in disrupting MDCK cell morphogen-
esis.
Loss of epithelial cell polarity is often accompanied with changes
in EMT marker gene expression. Thus, we examined the roles of
TIMP-1 in the regulation of established EMT markers. As shown
in Figure 3, TIMP-1 effectively downregulated E-cadherin
expression and upregulated the mesenchymal markers N-cad-
herin, fibronectin, and vimentin (Fig. 3A). Interestingly, TIMP-1
upregulated the expression of the EMT transcription factors
Figure 4. TIMP-1, but not GM6001 treatment, enhances MDCK
cell migration and invasion. A. MDCK-Neo, -T1, and –T1D cells were
incubated with 25 mM GM6001 and cell lysates were collected at the
indicated time points, followed by immunoblotting analysis for Akt and
ERKs. B. Cell migration was determined using a Transwell chamber
assay for 18 h. The total number of cells that migrated to the lower side
of the filter were counted using microscopy at 100X. C. Cell invasion
was assessed using a BioCoat Matrigel Invasion Chamber for 16 h. The
total number of cells that invaded to the lower side of the filter were
counted using microscopy at 100X. The experiment was done in
triplicates and the data is representative of three independent
experiments. Each bar represents the mean 6 s.d. Means with different
letters (a, b, c) are significantly different from one another at P value
,0.05 (ANOVA followed by Newman-Keuls test) and asterisk (*)
indicates a P value ,0.01 using a paired T-test.
doi:10.1371/journal.pone.0038773.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38773Figure 5. TIMP-1, independent of its MMP-inhibitory domain, upregulates the MT1-MMP/MMP-2 axis in MDCK cells. MDCK-Neo, -T1,
and T1D cells were untreated (-) or treated (+) with ConA for 18 hr. A. MT1-MMP, MMP-2, and MMP-9 RNA levels were determined by semi-
quantitative RT-PCR. B. Cell lysates and conditioned media were resolved by reducing 10% SDS-PAGE followed by immunoblot analysis of MT1-MMP
and MMP-2. C. Conditioned media were analyzed by gelatin zymography. P, pro-MMP-2: I, intermediate form of MMP-2: A, active MMP-2.
doi:10.1371/journal.pone.0038773.g005
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SNAIL expression (Fig. 3B). When we examined the effects of
TIMP-1 on cell migration, which is a functional hallmark of EMT,
both MDCK-T1 and MDCK-T1D cells displayed a more motile
phenotype, as assessed by a scratch wound assay, when compared
to MDCK-Neo cells (Fig. 3C). We also performed a modified
Boyden chamber migration assay to better quantitate the effects of
TIMP-1 and T1D expression on MDCK cell migration. As shown
in Figure 4B, 3–4 fold increases in cell migration were detected in
MDCK-T1 and MDCK-T1D cells compared to MDCK-Neo
cells (T1, T1 D vs. Neo in the absence of GM6001 treatment).
These results demonstrate that the ability of TIMP-1 to induce
EMT in MDCK cells is not mediated by its MMP inhibitory
domain and thus is independent of its ability to inhibit MMP
activity. To further evaluate a potential contribution of MMP
inhibition to the TIMP-1-mediated EMT process, cells were
treated with GM6001, a broad-spectrum MMP inhibitor, and
examined for activation of Akt and Erks and for cell motility. As
shown in Figure 4A, neither Akt nor Erks activation was altered in
MDCK-Neo cells after GM6001 treatment. These results are
consistent with the notion, and previous finding [22,23,24,25], that
TIMP-1-induced survival signaling is independent of its MMP-
inhibitory function. Interestingly, however, motility of MDCK-T1
and MDCK-T1D cells appears to be slightly reduced in the
presence of GM6001 (Fig. 4B), suggesting the potential involve-
ment of MMP activity for induction of cell motility.
EMT has been linked to enhanced tumor cell invasion [4].
Therefore, we compared the invasive capacity of MDCK-Neo,
MDCK-T1 and MDCK-T1D cells using a Matrigel invasion
assay. As shown in Figure 4C, both MDCK-T1 and MDCK-T1D
cells readily invaded through Matrigel, when compared to
MDCK-Neo cells, with MDCK-T1D cells exhibiting the highest
invasive activity. Interestingly, TIMP-1- and T1D-induced
MDCK invasion of Matrigel was partially sensitive to GM6001,
suggesting a role for metalloproteinase activity in this process.
Based on these results, we hypothesized that the enhanced
invasiveness of both MDCK-T1 and MDCK-T1D cells is partly
dependent on TIMP-1 signaling-mediated upregulation of matrix
metalloproteinase that is less sensitive to TIMP-1 for its enzymatic
inhibition, such as MT1-MMP [37,38,39]. Indeed, analyses of
MT1-MMP expression revealed increased MT1-MMP mRNA
and protein in MDCK-T1 and MDCK-T1D cells when compared
to MDCK-Neo cells (Fig. 5A and 5B, lanes 1–3). In addition,
MDCK-T1 and MDCK-T1D cells exhibited higher levels of
MMP-2 but reduced levels of MMP-9 mRNA (Fig. 5A, lanes 1–3).
Consistently, gelatin zymographic analysis showed increased
MMP-2 and decreased MMP-9 protein expression in MDCK-
T1 and MDCK-T1D cells when compared to MDCK-Neo cells
(Fig. 5C, top band, lanes 1–3). Increased MMP-2 expression was
also confirmed by immunoblot analysis (Fig. 5B, middle panel,
lanes 1–3). MT1-MMP is a major activator of pro-MMP-2 [40].
To evaluate the functional significance of TIMP-1 upregulation of
MT1-MMP, MDCK-T1, MDCK-T1D and MDCK-Neo cells
were treated with lectin ConA, since MT1-MMP-dependent pro-
MMP-2 activation requires stimulation with the lectin ConA [41].
Consistent with the higher levels of MT1-MMP expression in
MDCK-T1 and MDCK-T1D cells, ConA treatment of these cells
resulted in appearance of active MMP-2 (,62 kDa) in the
supernatant, as determined by immunoblot analyses and zymo-
graphy (Fig. 5B and 5C).
To determine the functional significance of MT1-MMP for
increased MMP-2 activation in MDCK-T1 and MDCK-T1D
cells, MT1-MMP expression was inhibited in these cells using 2
different siRNAs targeted to MT1-MMP. Immunoblot analysis
confirmed significant downregulation of MT1-MMP expression in
both MDCK-T1 and MDCK-T1D cells (top panels in Fig. 6A and
6B, respectively) upon siRNA transfection. Importantly, MT1-
MMP knockdown resulted in drastic inhibition of MMP-2
activation upon ConA treatment. It should be noted that MT1-
MMP knockdown had little effect on the expression levels of
MMP-2 and MMP-9.
Taken together, we propose that TIMP-1 signaling, indepen-
dent of its MMP-inhibitory domain, regulates expression of a set of
genes such as EMT transcription factors, epithelial/mesenchymal
markers, MT1-MMP, MMP-2 and MMP-9. We also propose that
increased MT1-MMP expression on the cell surface plays a critical
role in MMP-2 activation as depicted in Figure 7.
Figure 6. Knockdown of MT1-MMP abrogated MMP-2 activa-
tion in the MDCK-T1, T1D cells. MDCK-T1 (A) and MDCK-T1D (B)
cells in the absence or presence of control or MT1-MMP siRNAs were
untreated (-) or treated (+) with ConA for 18 hr. The protein levels of
MT1-MMP in cell lysates and MMP-2 in conditioned media were
determined by immunoblot analysis. Conditioned media were analyzed
by gelatin zymography. P, pro-MMP-2: I, intermediate form of MMP-2: A,
active MMP-2.
doi:10.1371/journal.pone.0038773.g006
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The present study demonstrated a novel function of TIMP-1 in
inducing EMT transcription factor expression and activating the
MT1-MMP/MMP-2 axis, leading to induction of the EMT-like
process in MDCK cells. Taking these results together with our
previous findings, we propose a working model for pleiotropic
activities of TIMP-1 as depicted in Figure 7. The C-terminal
domain of TIMP-1 interacts with a cell surface receptor, which in
turn activates signaling molecules such as FAK, PI3K, Akt, and
MAPK, thereby inducing cell survival and EMT [22,23,24,25]. In
human breast epithelial MCF10A cells, we previously identified
the tetraspanin, CD63, as a cell surface receptor for TIMP-1, and
TIMP-1 activates an integrin b1 signaling complex in a CD63-
dependent manner [25]. Since the canine counterpart of the
human CD63 gene has not been characterized and the
commercially available antibodies against CD63 failed to detect
canine proteins, we could not investigate the involvement of CD63
in TIMP-1-mediated EMT process in the MDCK model.
Nonetheless, similar to TIMP-1 interactions with CD63 and
subsequent signal transduction in breast epithelial cells, the N-
terminal MMP-inhibitory domain was not necessary for TIMP-1
signaling in MDCK cells.
Our novel finding of TIMP-1 regulation of MT1-MMP, MMP-
2, and MMP-9 expression may bring a paradigm shift in regards to
our understanding of TIMP-19s function as an endogenous
regulator of MMPs. The C-terminal part of TIMP-1functions as
a signaling molecule and regulates the MT1-MMP/MMP-2 axis,
whereas the N-terminal domain of TIMP-1 effectively inhibits the
enzymatic activity of MMP-2, but not of MT1-MMP. These
paradoxical roles of TIMP-1 in both activating an MMP cascade
and inhibiting MMP activity are likely to be modulated by the
availability of the TIMP-1 binding cell surface proteins such as
CD63 as well as the localization of TIMP-1 (soluble vs.
pericellular). While the N-terminal MMP inhibitory domain of
TIMP-1 interacts with and inhibits active MMPs such as MMP-2
and MMP-9, the C-terminal domain of TIMP-1 binds to pro-
MMP-9. Thus, it is plausible that pro-MMP-9 and CD63 may
compete for binding to the C-terminal domain of TIMP-1, and
thereby pro-MMP-9 abrogates TIMP-19s signaling capacity. This
may provide an explanation for unexpected, inverse correlation
between MMP-9 expression and tumor promotion. [42]. Similar-
Figure 7. A working model of TIMP-1 regulation of cell survival and MT1-MMP/MMP2 axis during EMT. TIMP-1 interacts with cell
surface protein(s) via its C-terminal domain, resulting in activation of cell survival signaling pathways and regulation of gene expression. Increased
MT1-MMP expression on the cell surface promotes MMP-2 activation. The pro-MMP-9 protein can interact with the C-terminal domain of TIMP-1, and
thereby may reduce TIMP-19s signaling capacity. TIMP-1 signaling-mediated downregulation of MMP-9 expression allows TIMP-1, free of pro-MMP-9,
to further promote cell signaling, a positive feedback signal amplification.
doi:10.1371/journal.pone.0038773.g007
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fibrosarcoma cells increased intravasation and lung metastasis in
the chick embryo chorioallantoic membrane model [43]. In the
present study, we found that TIMP-1 signaling downregulates
MMP-9 expression. Our model predicts that TIMP-1 molecules,
which are free of pro-MMP-9, would effectively interact with its
cell surface binding partner for cell signaling. Thus, TIMP-19s
ability to downregulate MMP-9 expression through TIMP-1
mediated cell signaling may indirectly promote TIMP-19s
signaling capacity, resulting in a positive feedback amplification
of TIMP-1 signaling.
The present study demonstrated that TIMP-1 signaling
upregulates several EMT transcription factors and MT1-MMP
expression. This is of particular importance in view that MT1-
MMP is among the triad of MMPs (MT1- MT2- and MT3-
MMPs), essential for invasive behavior of tumor cells [44].
Moreover, the relevance of MT1-MMP to human cancers is best
demonstrated, as it is suggested as a biomarker or as a potential
tumor target [45,46,47,48,49,50]. Consistent with our finding,
previous studies showed that increased MT1-MMP expression
promotes the EMT-like properties including cell invasion, which is
associated with increased EMT transcription factors, such as Snail,
Slug, and Sip1 [10,51,52,53]. Zeb1 and Twist are more commonly
expressed in metastatic tumors compared to the primary tumors
[54] and Twist may function upstream of Snail and Zeb1 [55].
Unique and overlapping roles of these transcription factors for the
regulation of epithelial/mesenchymal marker expression as well as
MMPs during the TIMP-1-mediated EMT process remain to be
fully investigated.
Collectively, our findings suggest a model in which TIMP-1
functions as signaling molecule and also as an endogenous
inhibitor of MMPs. Thus, in spite of the fact that TIMP-1, as
opposed to TIMP-2, does not interact with and inhibit MT1-
MMP, TIMP-1 may act as a key regulator of MT1-MMP/MMP-
2 axis. This concept represents a paradigm shift in the current view
of TIMP-1/MT1-MMP interactions and functions during cancer
development/progression. This information may also be useful in
designing more rational, mechanism-based therapeutic interven-
tions aimed at modulating activities of MMPs and TIMPs.
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